Meet the team
Co-Founder Directors & members of the Leadership Team
Dr Steve McConchie
Steve has worked in clinical development for nearly 25 years with AZ where he successfully delivered numerous oncology and haematology clinical development programmes.
Since forming Aptus Clinical, he and his expert team continue to support the design, conduct and delivery of innovative early phase clinical studies in oncology and rare diseases for a broad range of clients.
He is a member of the Scientific Innovation and Advisory Committee of the Bioindustry Association.
Chief Commercial Officer
A time proven project leader and line manager with 30 years’ industry experience in UK and Sweden. During his career he has worked across a broad range of disciplines, including clinical, laboratory and sales and marketing, in numerous therapeutic areas, including respiratory, oncology, CNS, infection and ophthalmology.
Since co-founding Aptus Clinical, Jonathan has helped build the business and grow the client portfolio.
Chief Governance Officer
Anita trained as a pharmacist and has 22 years’ clinical research experience across all development phases and with various pharma companies including GSK, Sanofi Winthrop, 3M and AstraZeneca.
Since co-founding Aptus Clinical, Anita has brought her decades of functional experience to establish a highly effective clinical operations team as well as implementing a fully integrated procedural infrastructure for client support.
Additional members of Leadership Team
Head of Clinical Services
Karen Sanville is our Head of Clinical Services. She spent 26 years at AstraZeneca, where she headed up UK Clinical Operations before moving to Quintiles as Vice President, Project Leadership Oncology.
Risk, Governance and Compliance Lead
Tessa Clarke is our Risk, Governance and Compliance Lead and has more than 20 years’ experience in clinical research. She has also been extensively involved in supporting and managing our Quality Management System.
Clinical Development Experts
Dr Glen Clack
MB BS MD FFPM
Chief Medical Officer
As Chief Medical Officer, Glen ensures the highest standards are achieved in the design, implementation and medical monitoring of clinical studies.
Glen has experience in all phases of clinical development, but now focusses on translational medicine, overseeing the early development of small molecule anti-cancer compounds. Areas of expertise include hormone manipulation, DNA damage repair, MTOR/PI3K/AKT pathway, anti-sense oligonucleotide and tumour genetic drivers.
Glen holds honorary academic positions at Manchester and Sheffield Universities.
Dr Paul Elvin
Chief Translational Science Officer
As Chief Translational Science Officer, Paul provides specialist bioscience and translational science input to preclinical and clinical drug projects.
During his 27 years’ experience in cancer drug discovery at AZ, Paul provided successful scientific leadership for both small molecule and therapeutic antibody projects, from target identification through early phase clinical studies. He has broad experience in the design and implementation of translational science programs, including due diligence for late stage preclinical and clinical opportunities.
Clinical Project Director
As Clinical Development Director, Ian drives performance, provides multi-disciplinary global teams with objectives, clarity of direction and effectively motivates teams to ensure oncology clinical operations are delivered to a high standard.
Ian has over 18 years' experience across all phases of clinical development with a proven track record of successfully delivering complex global projects. He combines technical prowess with strong interpersonal capabilities to positively influence decision making and build strong professional relationships.
Chief Statistical Officer
As Chief Statistical Officer, Nicola is responsible for the statistical integrity of clinical studies and supporting submissions to international regulatory authorities.
While Statistical Science Director at AZ, she was accountable for the provision of statistical input and strategy to drug development programmes for both oncology and infection, spanning Phase I to IV. Nicola designed and defended the Tagrisso® programme to the FDA and EMA.